Retatrutide: record-breaking weight loss — and a surprising benefit for aching joints

I've already written about retatrutide as a next-generation weight-loss medication being compared with tirzepatide (Mounjaro). This year, two things changed: the pivotal phase 3 data behind retatrutide's likely approval was published in full, and a second trial revealed a benefit I did not expect to see reported this clearly — meaningful relief from osteoarthritis pain. I want to walk through both, because together they change how I think about this medication's potential role.

Retatrutide is a "triple agonist" — a single molecule that activates three separate hormone receptors: GLP-1, GIP, and glucagon. Semaglutide (Wegovy, Ozempic) acts on GLP-1 alone; tirzepatide (Mounjaro, Zepbound) combines GLP-1 and GIP. Adding glucagon receptor activity, which increases energy expenditure in addition to appetite suppression, is the theoretical reason retatrutide has produced the largest weight-loss numbers we've seen from an injectable medication to date.

The pivotal trial, TRIUMPH-1, enrolled 2,339 adults with obesity or overweight and at least one weight-related health condition, but without diabetes, and followed them for 80 weeks against placebo. The results, by dose: the 4 mg dose produced average weight loss of 19.0% (47.2 lb); the 9 mg dose, 25.9% (64.4 lb); and the 12 mg dose, 28.3% (70.3 lb). In an extended follow-up to 104 weeks among patients with BMI 35 or higher on the 12 mg dose, average weight loss reached 30.3% (85 lb). Perhaps the single most striking figure: 45.3% of patients on the 12 mg dose lost 30% or more of their body weight — a threshold that historically has only been achievable with bariatric surgery. That is a genuinely new category of outcome for a medication, and it's the reason retatrutide is generating so much attention.

These benefits come with a cost in tolerability that scales with dose. Nausea was reported by 28.6%, 38.4%, and 42.4% of patients at increasing doses, with diarrhea, constipation, and vomiting also more common at higher doses. Discontinuation due to side effects ranged from 4.1% at the lowest dose studied to 11.3% at the highest. This is a reminder that, as with every medication in this class, more weight loss on paper does not automatically mean the right choice for every patient — tolerability has to be part of the conversation from day one, and dose escalation should be gradual and individualized.

The second piece of news comes from a separate pivotal trial, TRIUMPH-4, which found that retatrutide delivered not only substantial weight loss (Lilly has reported average loss of up to roughly 71 lb in this trial) but also meaningful relief from osteoarthritis pain in patients with both obesity and knee osteoarthritis. This matters enormously in practice. Osteoarthritis, particularly of the knees and hips, is one of the most common and disabling consequences of long-term excess weight, both because of the direct mechanical load on joints and because of the inflammatory effects of excess fat tissue. Weight loss has always been recommended as a cornerstone of osteoarthritis management, but until now we haven't had trial-level evidence, from a weight-loss drug specifically, quantifying how much joint pain relief follows. This positions retatrutide as potentially useful for a very specific and very large group of patients: those whose obesity is compounded by joint pain that limits the exercise we'd otherwise want them doing.

Where does this leave patients today? Retatrutide is not yet FDA-approved — Lilly has indicated it intends to file for approval based on this data, and regulatory review will take time, likely into 2027 for a final decision. For now, our approved options remain semaglutide and tirzepatide, both of which are excellent medications with a much longer track record. When retatrutide does become available, I expect it to be particularly relevant for patients who have not achieved adequate weight loss on existing GLP-1 or GLP-1/GIP medications, patients with higher BMI who may benefit from surgery-level weight loss without surgery, and patients whose obesity is significantly limited by joint pain.

As always with this rapidly evolving drug class, my advice is the same: these are powerful, effective medications, but they work best as part of a comprehensive plan that includes nutrition, resistance exercise to protect muscle mass during weight loss, and close medical supervision — not as a stand-alone fix. The data keep getting better; the fundamentals of good care around these medications haven't changed.

Sources: TRIUMPH-1 phase 3 trial results (AJMC, Clinical Trials Arena, 2026); TRIUMPH-4 phase 3 trial press release, Eli Lilly and Company, 2026.